Spotlight -

PBMI Innovators|

2026 State of Pharmacy survey results available now|

Our July 2026 issue

|Articles|September 1, 2002

Liability crisis attracts attention on Capitol Hill

House panel examines soaring insurance rates, while analysts paint gloomypicture for M+C program

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Related Content

States are stepping up healthcare oversight and regulation

April 8th 2026

Not Red. Not Blue. Healthcare Is a Populist Issue, Says Costa | AMCP Nexus 2025

ByDenise Myshko

October 27th 2025

Businessman drawing checkmarks on virtual staircase steps toward achieving goals | image credit" ©Nirusmee stock.adobe.com

Developing Winning Supplemental Benefits Packages

ByEric Levine, M.P.H.,Mark Tepper,Spike Cheever

Published: March 5th 2025 | Updated: March 4th 2025

Fending Off Major Cuts May Be the Bigger Fight, But Medicaid Work Requirements Are Also a Bad Idea | Leanne Berge, J.D., CEO of Community Health Plan of Washington

ByPeter Wehrwein, Managing Editor

March 4th 2025

Medicaid Is on the GOP Chopping Block. Could It Be Because of a Misunderstanding? | Leanne Berge, J.D., CEO of Community Health Plan of Washington

ByPeter Wehrwein, Managing Editor

February 27th 2025

Latest CME

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care

Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care

August 20, 2026

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

27th Annual International Lung Cancer Congress®

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

26th Annual International Lung Cancer Congress

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

20th Annual New York Lung Cancers Symposium®

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Mara Antonoff, MD, FACS; Laura Alder, MD; Stephanie Worrell, MD, FACS

Trending on Managed Healthcare Executive

New hypertension drugs show no advantage over older generics

Physicians may be the key for affordable healthcare

Prior authorization isn’t shrinking. Its savings are

Conversations with Perry and Friends: Dipak Patek, CEO of Globo

What employees may miss when they buy drugs directly online